Search Results - "LEWITT, P"

1.12.2 ADVANCES IN CSF BIOMARKERS OF PARKINSON'S DISEASE by LeWitt, P

Get full text

Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases by Lorenzl, S, Albers, D.S, LeWitt, P.A, Chirichigno, J.W, Hilgenberg, S.L, Cudkowicz, M.E, Beal, M.F

“…Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of diseases such as Alzheimer's Disease (AD) and amyotrophic lateral sclerosis (ALS)…”
Get full text

2.244 Efficacy of rotigotine transdermal patch as adjunct to levodopa in subgroups of advanced-stage Parkinson's patients by LeWitt, P

Get full text

Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions by Loeffler, D A, Connor, J R, Juneau, P L, Snyder, B S, Kanaley, L, DeMaggio, A J, Nguyen, H, Brickman, C M, LeWitt, P A

“…Oxidant-mediated damage is suspected to be involved in the pathogenesis of several neurodegenerative disorders. Iron promotes conversion of hydrogen peroxide…”
Get more information

P1.135 Automated Parkinson's disease motor assessment for clinical and ambulatory monitoring by Heldman, D, Espay, A, LeWitt, P, Giuffrida, J

Get full text

Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders by Loeffler, D.A., LeWitt, P.A., Juneau, P.L., Sima, A.A.F., Nguyen, H.-U., DeMaggio, A.J., Brickman, C.M., Brewer, G.J., Dick, R.D., Troyer, M.D., Kanaley, L.

“…Ceruloplasmin (CP), the major plasma anti-oxidant and copper transport protein, is synthesized in several tissues, including the brain. We compared regional…”
Get full text

2.247 Safe and tolerable switching from oral dopaminergic agonists to transdermal rotigotine in Parkinson's disease by LeWitt, P, Boroojerdi, B

Get full text

Evaluation of a Measurement Strategy for Parkinson's Disease: Assessing Patient Health-Related Quality of Life by Damiano, A M, McGrath, M M, Willian, M K, Snyder, C F, LeWitt, P A, Reyes, P F, Richter, R R, Means, E D

“…This study evaluated the feasibility and psychometric properties of self-completed and telephone interview versions of a patient health-related quality-of-life…”
Get full text

Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial by Kurth, M. C., Adler, C. H., St. Hilaire, M., Singer, C., Waters, C., LeWitt, P., Chernik, D. A., Dorflinger, E. E., Yoo, K.

Get full text

Tolcapone in stable Parkinson's disease : Efficacy and safety of long-term treatment by WATERS, C. H, KURTH, M, BAILEY, P, SHULMAN, L. M, LEWITT, P, DORFLINGER, E, DEPTULA, D, PEDDER, S

Get full text

Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection by Lewitt, Peter A., Trosch, Richard M.

“…Three cases of adverse reactions to repeated intramuscular botulinum toxin A (BTA) injections are described: a persistent rash on the face at the site of…”
Get full text

Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience by Trosch, Richard M., Friedman, Joseph H., Lannon, Meg C., Pahwa, Rajesh, Smith, D., Seeberger, Lauren C., O'Brien, Christopher F., Lewitt, Peter A., Koller, William C.

“…We conducted a multicentered, retrospective review of clozapine's (CZP) effects on a range of psychiatric, sleep, cognitive, motor, and sensory disorders in…”
Get full text

Neuroprotection for Parkinson's disease by LeWitt, P A

“…Although still a disorder of unknown etiology, Parkinson's disease (PD) has provided a number of clues that have led to clinical trials of neuroprotection. For…”
Get more information

P2.147 Treatment of patients with early and advanced Parkinson's disease with transdermal rotigotine: safety and tolerability in elderly patients by Oertel, W, LeWitt, P, Watts, R, Grieger, F, Bauer, L, Boroojerdi, B

Get full text

L‐DOPA Does Not Enhance Hydroxyl Radical Formation in the Nigrostriatal Dopamine System of Rats with a Unilateral 6‐Hydroxydopamine Lesion by Camp, Dianne M., Loeffler, David A., LeWitt, Pater A.

“…The debate about the toxicity of L‐DOPA to dopaminergic neurons has not been resolved. Even though enzymatic and nonenzymatic metabolism of L‐DOPA can produce…”
Get full text

Levodopa in the treatment of Parkinson's disease: a consensus meeting by Agid, Y, Ahlskog, E, Albanese, A, Calne, D, Chase, T, De Yebenes, J, Factor, S, Fahn, S, Gershanik, O, Goetz, C, Koller, W, Kurth, M, Lang, A, Lees, A, Lewitt, P, Marsden, D, Melamed, E, Michel, P P, Mizuno, Y, Obeso, J, Oertel, W, Olanow, W, Poewe, W, Pollak, P, Tolosa, E

Get full text

Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease by Lewitt, Peter A.

“…Involuntary upward and lateral eye movements are described in two Parkinson's disease patients who also experience levodopa‐induced chreoathetoid limb…”
Get full text

Ceruloplasmin immunoreactivity in neurodegenerative disorders by Loeffler, D A, Sima, A A, LeWitt, P A

“…Ceruloplasmin (CP) is a 132 kd cuproprotein which, together with transferrin, provides the majority of anti-oxidant capacity in serum. Increased iron…”
Get more information

CO109 Patient-Reported Improvements in “Off”-Time Quality, Non-Motor Fluctuation Severity, and Medication Satisfaction in the Real-World Opti-on Study of Opicapone in Parkinson’s Disease by LeWitt, P., Klepitskaya, O., Serbin, M., Jen, E., Rattana, S., Trotter, J., Liang, G.

Get full text

Levodopa therapeutics: New treatment strategies by LeWitt, P A

“…Even though levodopa can provide effective therapy for symptomatic relief of parkinsonism, many patients deteriorate over time. This change may be related to a…”
Get full text